Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow

Haematologica

Volumn 102, Issue 11, 2017, Pages e427-e430

  Clinkenbeard, Erica L ^a   Hanudel, Mark R ^b   Stayrook, Keith R ^c   Appaiah, Hitesh Nidumanda ^a   Farrow, Emily G ^d   Cass, Taryn A ^a   Summers, Lelia J ^a   Ip, Colin S ^a   Hum, Julia M ^a   Thomas, Joseph C ^a   Ivan, Mircea ^c   Richine, Briana M ^c   Chan, Rebecca J ^c   Clemens, Thomas L ^e   Schipani, Ernestina ^f   Sabbagh, Yves ^g   Xu, Linlin ^a   Srour, Edward F ^c   Alvarez, Marta B ^c   Kacena, Melissa A ^c   Salusky, Isidro B ^b   Ganz, Tomas ^b   Nemeth, Elizabeta ^b   White, Kenneth E ^a   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 23; HEPCIDIN; PARATHYROID HORMONE; FIBROBLAST GROWTH FACTOR;

ANEMIA; BONE; BONE MARROW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DOWN REGULATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXIA; IRON DEFICIENCY; IRON METABOLISM; KIDNEY FUNCTION; LETTER; MORTALITY; MYELOID PROGENITOR CELL; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BLOOD; BONE MARROW CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE;

ANIMALS; BONE AND BONES; BONE MARROW; BONE MARROW CELLS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE;

EID: 85032672522     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.167882     Document Type: Letter

References (13)

1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia asso ciated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002; 13(2): 504-510.
2. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23): 2432-2439.
3. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11): 4393-4408.
4. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9): 2600-2608.
5. McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6): 549-558.
6. Hanudel MR, Chua K, Rappaport M, et al. Effects of Dietary Iron Intake and Chronic Kidney Disease on Fibroblast Growth Factor 23 Metabolism in Wild Type and Hepcidin Knockout Mice. Am J Physiol Renal Physiol. 2016: ajprenal 00281 02016.
7. Sabbagh Y, Graciolli FG, O’Brien S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27(8): 1757-1772.
8. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12): 3730-3735.
9. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011; 108(46): E1146-1155.
10. Chitteti BR, Cheng YH, Poteat B, et al. Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function. Blood. 2010; 115(16): 3239-3248.
11. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014; 289(14): 9795- 9810.
12. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res. 2014; 29(2): 361-369.
13. Guo L, Luo T, Fang Y, et al. Effects of erythropoietin on osteoblast proliferation and function. Clin Exp Med. 2014; 14(1): 69-76.